EMEA-001741-PIP07-22 - paediatric investigation plan

upadacitinib

Key facts

• Invented name:
  Rinvoq
• Active Substance:
  upadacitinib
• Therapeutic area:
  Dermatology
• Decision number:
  P/0383/2023
• PIP number:
  EMEA-001741-PIP07-22
• Pharmaceutical form(s):
  • Age-appropriate oral dosage form
  • Prolonged-release tablet
• Condition(s) / indication(s):
  Treatment of vitiligo
• Route(s) of administration:
  Oral use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  07/09/2023

Decision

P/0383/2023 : EMA decision of 7 September 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for upadacitinib (Rinvoq), (EMEA-001741-PIP07-22)

Reference Number: EMA/388229/2023